X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fc-gamma-riiia (371) 371
humans (322) 322
index medicus (247) 247
rituximab (169) 169
oncology (123) 123
immunology (119) 119
animals (108) 108
female (105) 105
anti-cd20 monoclonal-antibody (98) 98
chronic lymphocytic-leukemia (93) 93
receptors, igg - genetics (90) 90
male (88) 88
hematology (84) 84
antibodies, monoclonal - therapeutic use (82) 82
cancer (76) 76
non-hodgkins-lymphoma (76) 76
middle aged (71) 71
adult (70) 70
dependent cellular cytotoxicity (68) 68
monoclonal-antibody (67) 67
killer cells, natural - immunology (64) 64
aged (63) 63
follicular lymphoma (63) 63
natural-killer-cells (62) 62
antibodies, monoclonal, murine-derived (58) 58
antineoplastic agents - therapeutic use (57) 57
binding (57) 57
cytotoxicity (56) 56
immunotherapy (55) 55
polymorphism (55) 55
antibodies, monoclonal - pharmacology (54) 54
genotype (50) 50
medicine, research & experimental (50) 50
monoclonal antibodies (49) 49
treatment outcome (49) 49
antibody-dependent cell cytotoxicity (48) 48
adcc (47) 47
mice (46) 46
antibodies, monoclonal - immunology (44) 44
cell line, tumor (44) 44
fcγriiia (44) 44
in-vitro (44) 44
antigens, cd20 - immunology (42) 42
fc gamma riiia (42) 42
igg (42) 42
glycosylation (40) 40
in-vivo (39) 39
rheumatoid-arthritis (39) 39
biochemistry & molecular biology (38) 38
c-receptor polymorphisms (38) 38
polymorphism, genetic (38) 38
antibodies (37) 37
b-cell lymphoma (37) 37
receptors, igg - immunology (37) 37
antibody-dependent cell cytotoxicity - drug effects (35) 35
expression (35) 35
immunoglobulin-g (35) 35
antibody-dependent cell cytotoxicity - immunology (34) 34
cell biology (34) 34
predict response (34) 34
lymphomas (33) 33
analysis (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (32) 32
chemotherapy (32) 32
lymphoma (32) 32
pharmacology & pharmacy (32) 32
therapy (31) 31
antibody (30) 30
antineoplastic agents - pharmacology (30) 30
biotechnology & applied microbiology (30) 30
receptors, igg - metabolism (30) 30
research (30) 30
fc receptors (29) 29
nk cells (29) 29
activation (28) 28
b-lymphocytes - immunology (28) 28
health aspects (28) 28
antibodies, monoclonal, murine-derived - therapeutic use (27) 27
breast-cancer (27) 27
immune system diseases (27) 27
polymorphism, single nucleotide (27) 27
systemic-lupus-erythematosus (27) 27
t-cells (27) 27
aged, 80 and over (26) 26
care and treatment (26) 26
fucose (26) 26
immunoglobulin g (26) 26
trastuzumab (26) 26
clinical trials as topic (25) 25
hemic and lymphatic diseases (25) 25
immunoglobulin g - immunology (25) 25
monoclonal antibody (25) 25
natural killer cells (25) 25
prognosis (25) 25
antibodies, monoclonal, humanized (24) 24
cd20 (24) 24
genetic aspects (24) 24
killer cells, natural - metabolism (24) 24
review (24) 24
receptor polymorphisms (23) 23
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


SCIENCE TRANSLATIONAL MEDICINE, ISSN 1946-6234, 01/2018, Volume 10, Issue 424, p. eaan5488
Antibodies targeting immune checkpoints are emerging as potent and viable cancer therapies, but not all patients respond to these as single agents.... 
EPITHELIAL-MESENCHYMAL TRANSITION | MEDICINE, RESEARCH & EXPERIMENTAL | GROWTH-FACTOR-BETA | FC-GAMMA RIIIA | CANCER-ASSOCIATED FIBROBLASTS | NK CELLS | IN-VIVO | SQUAMOUS-CELL CARCINOMA | NATURAL-KILLER-CELL | OPEN-LABEL | TUMOR MICROENVIRONMENT | CELL BIOLOGY
Journal Article
Nature Reviews Immunology, ISSN 1474-1733, 05/2006, Volume 6, Issue 5, pp. 343 - 357
Journal Article
Blood, ISSN 0006-4971, 10/2007, Volume 110, Issue 7, pp. 2561 - 2564
The presence of valine (V) at position 158 of Fc-gamma Rllla (CD16) is known to improve clinical response to rituximab in indolent non-Hodgkin lymphoma (NHL).... 
PREDICT RESPONSE | ANTI-CD20 MONOCLONAL-ANTIBODY | FC-GAMMA-RIIIA | HUMAN-IGG | NON-HODGKINS-LYMPHOMA | HEMATOLOGY | CLINICAL-RESPONSE | Immunobiology
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 08/2019, Volume 25, Issue 16, pp. 4955 - 4965
Purpose: mAbs including cetuximab can induce antibody-dependent cellular cytotoxicity (ADCC) and cytokine production mediated via innate immune cells with the... 
CYTOKINE RESPONSE | GROWTH-FACTOR RECEPTOR | SINGLE-AGENT | RECOMBINANT HUMAN INTERLEUKIN-12 | NATURAL-KILLER-CELLS | EFFECTOR FUNCTIONS | ONCOLOGY | FC-GAMMA-RIIIA | I TRIAL | SUPPRESSOR-CELLS | T-CELLS
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2016, Volume 22, Issue 17, pp. 4405 - 4416
Purpose: Mogamulizumab (Mog), a humanized anti-CC chemokine receptor 4 (CCR4) mAb that mediates antibody-dependent cellular cytotoxicity (ADCC) using Fc gamma... 
NATURAL-KILLER-CELLS | ACTIVATION | VIVO | ONCOLOGY | IMMUNOTHERAPY | FC-GAMMA-RIIIA | MONOCLONAL-ANTIBODY KW-0761 | LYMPHOMA | CD16 | COMBINATION | TRANSPLANTATION
Journal Article
Journal Article
Journal Article
Autoimmunity Reviews, ISSN 1568-9972, 2010, Volume 10, Issue 1, pp. 3 - 7
Abstract Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disease whose pathogenesis is multifactorial lying on genetic, environmental factors... 
Allergy and Immunology | ACTIVATION | FC-GAMMA-RIIIA | DISEASE | IL-17 | POLYMORPHISM | IMMUNOLOGY | B-CELL BIOLOGY | EXPRESSION | ASSOCIATION | RISK HAPLOTYPE | T-CELLS | Lupus | Autoimmunity | Development and progression | Systemic lupus erythematosus | Autoantibodies
Journal Article